Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.
ViaCyte is focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). The acquisition of ViaCyte provides Vertex with complementary assets, capabilities and technologies including additional human stem cell lines, intellectual property around stem cell differentiation, and Good Manufacturing Practice (GMP) manufacturing facilities for cell-based therapies that could accelerate Vertex's ongoing T1D programs.
The acquisition also provides access to novel hypoimmune stem cell assets via the ViaCyte collaboration with CRISPR Therapeutics.
Vertex anticipates the acquisition will close later this year, subject to certain customary conditions being met.
Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease
Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY
Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology
Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes
U.S. Weekly Jobless Claims Unexpectedly Dip To 224,000
UK GDP Rises More Than Expected
Bay Street Likely To Open On Mixed Note
